BioLife Solutions (NASDAQ:BLFS) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Key Points

• BioLife Solutions beat expectations in its latest quarter, reporting EPS of $0.04 versus the $0.01 consensus and revenue of $27.5 million, also above estimates of $25.66 million.
• Growth remained strong with Q1 revenue up 25% year over year and adjusted EBITDA of $6.2 million, though gross margin was pressured by temporary bag yield issues.
• The company reaffirmed 2026 guidance for $112.5 million to $115 million in revenue and expects full-year GAAP net income, while also expanding into new products like CellSeal and PanTHERA.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) released its earnings results on Thursday. The medical equipment provider reported $0.04 EPS for the quarter, topping analysts' consensus estimates of $0.01 by $0.03, Zacks reports. BioLife Solutions had a negative net margin of 2.80% and a positive return on equity of 1.83%. The business had revenue of $27.50 million for the quarter, compared to the consensus estimate of $25.66 million.

Here are the key takeaways from BioLife Solutions' conference call:

• Q1 revenue was $27.5 million, up 25% year‑over‑year, with adjusted EBITDA of $6.2 million (22% of revenue); biopreservation media (BPM) drove growth and represents over 85% of revenue with top 20 BPM customers providing strong visibility.
• Bag yield issues pressured gross margin (adjusted gross margin down to 64% from 68%) and adjusted EBITDA percentage; management says the issue is temporary, customer notifications and a 90‑day selection window are underway, and margin recovery is expected by Q4 2026 or Q1 2027 depending on inventory burn.
• The company reaffirmed 2026 guidance of $112.5M–$115M revenue (17%–20% growth), expects mid‑60s gross margins, and anticipates achieving full‑year GAAP net income and expanded adjusted EBITDA margins for 2026.
• BioLife is expanding beyond BPM — including CellSeal, hPL, the award‑winning CryoCase, and a planned PanTHERA Q4 launch — and says cross‑selling these products could raise revenue per dose by 2 to 3 times versus BPM alone.

BioLife Solutions Stock Performance

Shares of NASDAQ:BLFS opened at $22.04 on Friday. The company has a market cap of $1.08 billion, a PE ratio of -275.47 and a beta of 1.97. BioLife Solutions has a 52 week low of $17.86 and a 52 week high of $29.62. The firm has a 50 day simple moving average of $20.36 and a 200 day simple moving average of $23.34.

Insiders Place Their Bets

In other news, insider Karen A. Foster sold 96,923 shares of the stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $20.15, for a total value of $1,952,998.45. Following the completion of the sale, the insider directly owned 113,742 shares of the company's stock, valued at $2,291,901.30. This represents a 46.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders have sold 99,641 shares of company stock worth $2,009,000. Insiders own 2.20% of the company's stock.

Institutional Investors Weigh In On BioLife Solutions

A number of institutional investors have recently modified their holdings of the stock. T. Rowe Price Investment Management Inc. increased its stake in shares of BioLife Solutions by 27.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 5,180,824 shares of the medical equipment provider's stock worth $125,273,000 after acquiring an additional 1,113,972 shares during the last quarter. Invesco Ltd. grew its stake in BioLife Solutions by 9.2% in the fourth quarter. Invesco Ltd. now owns 3,932,191 shares of the medical equipment provider's stock valued at $95,080,000 after purchasing an additional 332,747 shares in the last quarter. Qube Research & Technologies Ltd grew its stake in BioLife Solutions by 2,399.5% in the second quarter. Qube Research & Technologies Ltd now owns 248,474 shares of the medical equipment provider's stock valued at $5,352,000 after purchasing an additional 238,533 shares in the last quarter. Heights Point Management LP acquired a new position in BioLife Solutions in the 4th quarter worth about $5,260,000. Finally, Ameriprise Financial Inc. increased its position in BioLife Solutions by 11.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,080,371 shares of the medical equipment provider's stock worth $23,271,000 after purchasing an additional 109,959 shares during the last quarter. Institutional investors and hedge funds own 93.24% of the company's stock.

Analyst Ratings Changes

Several research analysts have issued reports on BLFS shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of BioLife Solutions in a report on Monday, April 20th. Wall Street Zen upgraded BioLife Solutions from a "hold" rating to a "buy" rating in a report on Saturday, February 28th. Finally, Zacks Research raised BioLife Solutions from a "hold" rating to a "strong-buy" rating in a research report on Friday, January 23rd. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, BioLife Solutions presently has a consensus rating of "Moderate Buy" and a consensus target price of $32.00.

BioLife Solutions News Roundup

Here are the key news stories impacting BioLife Solutions this week:

• Positive Sentiment: BioLife reported Q1 2026 revenue of $27.5 million, up 25% year over year, with GAAP net income of $1.2 million and adjusted EBITDA of $6.2 million, showing improved profitability and operational leverage. BioLife Solutions Reports First Quarter 2026 Financial Results
• Positive Sentiment: The company beat earnings expectations, posting $0.04 per share versus the $0.01 consensus estimate, while revenue also came in above forecasts at $27.5 million versus $25.66 million expected. BioLife Solutions, Inc. (BLFS) Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: BioLife also updated FY2026 revenue guidance to $112.5 million-$115.0 million, which brackets the market consensus near $113.0 million and suggests management still sees steady full-year demand. BioLife Solutions earnings transcript
• Neutral Sentiment: Analysts continue to rate BLFS a “Moderate Buy,” reinforcing a constructive long-term outlook but not signaling a major new catalyst. BioLife Solutions Receives Consensus Recommendation of Moderate Buy from Analysts
• Neutral Sentiment: A comparison article versus Organigram Global added little directly relevant new information for BLFS investors. Head-To-Head Contrast: Organigram Global versus BioLife Solutions

About BioLife Solutions

BioLife Solutions NASDAQ: BLFS specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife's product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company's flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.